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Summary Despite the five million children who have been screened for neuroblastoma in Japan through
detection of catecholamine metabolites, it is still uncertain whether screening for this disease is beneficial. The
Japanese study has clearly indicated that screening at 6 months or earlier leads to heavy overdiagnosis. It is
shown in this paper that screening at a later age may give the same reduction in mortality with possibly less
overdiagnosis. However, it is estimated that, even with two screens at 12 and 18 months, the reduction in
mortality would not greatly exceed 25%, under realistic hypotheses on the length of the preclinical phase of
the disease. The evaluation of the efficacy of this screening strategy would need the recruitment of half a
million children per year over 5-7 years and the follow-up of an equal number of controls. Such a trial would
improve our knowledge of the natural history of the disease and might help to answer some questions raised
recently regarding its biological heterogeneity.
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Neuroblastoma is a tumour of the sympathetic nervous
system which derives from embryonic cells of the neural
crest. It is the most frequent solid tumour in childhood, and
is characterised by strongly contrasting survival rates between
young children with an early-stage tumour and older children
with a late-stage tumour (Berthold et al., 1990; Bernstein et
al., 1992; Mathieu et al., 1993). The difference is so large
(95% vs 20% respectively), and the progress in the treatment
of late-stage, late-age tumours so slow (Huddart et al., 1993),
that it is tempting to screen for the tumour at an early age. A
simple non-invasive test exists (Tuchman et al., 1987; Math-
ieu et al., 1993), and a mass screening programme was
started in Japan in 1985 after several pilot studies. After
more than 7 years of operation, however, there is still little
evidence that screening for neuroblastoma is effective (Han-
awa et al., 1990; Nishi et al., 1992), and several researchers
have expressed doubts about the appropriateness of the pro-
cedure set up in Japan, suggesting in particular that screening
at 6 months is too early (Cole and Parker, 1990; Bessho et
al., 1991; Parker et al., 1991). Screening efficacy for neuro-
blastoma is still an open question, and before embarking on
large evaluation trials it is necessary to review the epide-
miological and biological evidence to assess whether the
evaluation of screening at an age older than 6 months is
feasible, or even if it is needed at all, given the progress
recently made on understanding the biology of the disease
which suggests that neuroblastoma is not a single disease
entity. This article is a report of work carried out within the
Study Group for the Evaluation of Neuroblastoma Screening
in Europe (SENSE)' to try to answer these questions. It first
reviews briefly the epidemiology of the disease and the princi-
ple of screening through detection of cathecolamine metabo-
lites. It then examines the results of programmes which
screen for the disease at 6 months or earlier: this shows that
this strategy mainly detects a mild form- of the disease which
would not surface clinically in the absence of screening (over-
diagnosis). Finally, it compares the efficacy of screening
neuroblastoma at several ages as if it were a single disease
entity and discusses the value of different screening strategies
in the light of some recent biological results. The main
emphasis is on epidemiological and biostatistical arguments,
but it is essential to bear in mind several aspects of the
biology of the disease in interpreting them, and in making a
final decision on whether to conduct a screening trial, and on
which screening strategy to evaluate.
The epidemiology of neuroblastoma
Neuroblastoma occurs at various primary sites (Mathieu et
al., 1993). Therefore, its incidence is impossible to assess
from routine data published by general cancer registries
which record cancer by topographical site. The recent study
of childhood cancer incidence by the International Agency
for Research on Cancer based on diagnostic groups defined
according to histology (Parkin et al., 1988) enabled interna-
tional variation in this disease to be studied (Stiller et al.,
1992). The cumulative incidence up to age 15 years varied
from 50 to about 170 per million among the 30 populations
in which age-specific incidence was measured. There was a
slight excess risk in males and, in addition, differences
between various ethnic groups within the same population
were evident; although part of the variation may be explain-
ed by underdiagnosis in some populations, the latter observa-
tion suggests that some variation must have an aetiological
basis. Incidence in selected countries and average incidence in
Europe are shown in Table I. It is noticeable that the differ-
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Table I Incidence of neuroblastoma' in selected countries and average incidence in Europe
around 1980
.4ge w ears)
Countr-i 0 1 2 3 4 5 6 8 9 10-14 CR2
Europe 33 21 17 13 10 6 4 3 2 1.5 1 116
Canada 36 26 23 13 6 8 4 2 2 1.3 1 126
Japan 24 23 17 16 10 7 3 2 1 2 1.3 112
U-SA 52 29 22 6 7 5 4 3 3 1.3 1.3 139
'Per million person-years: data taken from Parkin et al. (1988). Registr data have been
pooled within countries. 'Cumulative risk before 15th anniversary per million births.
ences are greater in the first year of life. an age for which
under( over) diagnosis is also the highest. The incidence has
increased with time in Denmark and the UK (Carlsen. 1986:
Stiller, 1993). and the changes are especially marked in the
first 2 years of life.
The current overall 5 year survival for neuroblastoma is of
the order of 50%. This figure hides a wide heterogeneity
among patients: patients with early-stage disease diagnosed
before 1 year of age have an extremely good prognosis (5
year survival 95%). while patients with late-stage neuroblas-
tomas diagnosed after 18 months have a 5 year survival of
the order of 20%0 both age and stage are prognostic factors,
and the shape of the survival curves differs according to age
at diagnosis (Table II and Figure 1).
The overall 5 year survival has increased with time in the
three countries where it has been documented (Silverberg et
al.. 1990: Stiller et al.. 1990: Sankila et al.. 1993). In the UK
it tripled between 1970 and 1980 from 15% to 43%. How-
ever. children diagnosed between age 2 and 9 years still had a
poor survival probability in 1985 (-25%), reflecting the fact
that the survival rate of late-stage patients has hardly im-
proved (Stiller et al.. 1990: Huddart et al.. 1993).
Since neuroblastoma is defined by its histology, mortality
data for this malignancy are not routinely available. In the
UK. however, information on death is available from
National Health Service Central Registers. enabling the
neuroblastoma mortality trend to be studied (Stiller. 1993).
An initial fall in mortality during the 1970s reflected the
improvement in survival, but there is a suggestion of an
increase more recently. which may result from a real increase
in the incidence of the disease in the UK. Other mortality
data based on smaller numbers of deaths have been pub-
lished (Carlsen. 1986; Bernstein et al.. 1992), and extensive
data have been published for Japan (Hanawa et al., 1990).
All these publications have shown an age-standardised
mortality rate of about 50 per million, and a 0-14 years
cumulative risk of death of about 65 per million around
1985. However. disagreements on past mortality are large.
and these early data may be less reliable (Birch et al.. 1987):
while in the small historical series of Denmark mortality
remained practically constant at 50 106, it decreased from 120
to 50 106 in Japan.
Screeling for neuroblastoma
If neuroblastoma were a disease progressing with age from
early stages to late stage. it would be justified to look for a
means of detecting the disease before it reaches a stage of
metastasis to bone and marrow, when the prognosis is very
poor. Catecholamine metabolites are present in excess in the
urine of most neuroblastoma patients: 85% of patients (Prit-
chard et al.. 1989: Berthold et al., 1991) or, according to
other sources (Worthington et al., 1988; Virdi et al., 1994).
more than 90% excrete these metabolites, it is thought that
they are detectable in the urine of children before symptoms
appear (the prevalence of catecholamine metabolites at diag-
nosis varies from 500o for stage I to 94% for stage IV).
Therefore, a screening test based on the measurment of
vanillylmandelic acid (VMA) and homovanillic acid (HVA)
levels in urine by high-performance liquid chromatography
Table I1 Five year survival probability of children with
neuroblastomaa by age at diagnosisb
.4ge at diagnosis tmonths)
1.5 6 12 18 24 30 36 48 60 120
0.86 0.80 0.54 0.39 0.35 0.28 0.24 0.24 0.30 0.36
'Data from the European Neuroblastoma Study Group. Chairman
ADJ Pearson. Children's Cancer Unit. Department of Child Health.
University of Newcastle upon Tyne. Medical School. Framlington
Place. Newcastle upon Tyne NE2 4HH. UK. bData for other ages
were linearly interpolated from the data shown in this table.
-~0.8
o- 0.6 - ~
c,0.4
, 0.2
o 12 24 26 48 60
Months since diagnosis
Figue 1 Shape of survival probability curves according to age
at diagnosis (U. 0-9: 0. 9-21: A. 21 +) Survival probability
was calculated from data provided by the 'Societe Franqaise
d'Oncologie Pediatfique.
(HPLC) has been developed (Tuchman et al.. 1987: Mathieu
et al.. 1993).
Screening for neuroblastoma at the age of 6 months was
started in selected areas of Japan at the beginning of the
1980s (Sawada et al., 1984. 1986). and was extended to a
nationwide mass screening programme in 1985. The coverage
of the screening programme increased with time. reaching
83% of eligible children in 1989. A review of 337 cases
detected at screening showed extremely good survival
(Sawada et al.. 1991). A detailed report of this proramme
was recently published (Sawada, 1992). but no convincing
evaluation of the programme efficacy has yet been either
camed out or is planned.
Several attempts to evaluate screening for neuroblastoma
have been set up (Berthold et al., 1992: Craft et al.. 1992:
Schilling et al.. 1992: Seviour et al.. 1992: Mathieu et al..
1993). among which the study in Quebec (Tuchman et al..
1990) is the most potentially informative, in so far as it was
planned and started as an evaluation of screening efficacy; all
children born in the province of Quebec during the 5 year
period starting 1 May 1989 were eligible for screening. VMA
and HVA were measured in urine specimens collected at 3
weeks and 6 months. At the end of the study the screening
programme offered screening to 450 000 children: the compli-
ance at 3 weeks was 92%. and at 6 months 76%. Mortality
from neuroblastoma in Quebec will be compared with
mortality in several unscreened populations of North
America. in which incidence and mortality have been demon-
strated to be similar to the prescreening levels in Quebec.Neuroblastoma screening evaluation
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Screening children at 6 months leads to overdiagnosis
A well-known adverse effect of screening for cancer is caused
by the detection of tumours which are histologically malig-
nant but clinically benign: in the absence of screening, such
tumours would not have surfaced clinically. Although in the
present situation the diagnosis test itself is safe, the cases
detected at screening may receive heav- therapy, which could
lead to excess deaths and long-term morbidity. Extensive
overdiagnosis could therefore be a strong argument against
the implementation of mass screening programmes for neuro-
blastoma.
The cumulative risk for neuroblastoma in children in
Japan was 112 106 before screening in 1980. In 1989. the
screening programme detected 122 cases per million children
tested at 6 months (Sawada. 1992): if. as is likely, the natural
incidence of neuroblastoma has not drastically changed in
recent years, we can conclude that most neuroblastomas
which would have occurred in this birth cohort at later ages
in the absence of screening were detected by the 1989 mass
screening. Therefore. very few cases older than 1 year should
have occurred since 1990, but this has not been observed.
Moreover, as it will be shown below, such a high prevalence
at screening is not compatible with the most optimistic
hypotheses on the length of the preclinical phase of the
disease during which high levels of VMA and HVA are
excreted in the urine of neuroblastoma patients not yet diag-
nosed. Similar arguments have been put forward previously
to suggest that screening at 6 months is not advisable
because overdiagnosis is too great (Carlsen. 1990: Goodman.
1991; Carlsen et al., 1992).
In the Quebec study. seven neuroblastoma patients were
detected at 3 weeks among 157459 infants tested (Woods et
al.. 1992a) and three cases of this birth cohort were false
negatives diagnosed before 6 months. Such a detection rate
would be equivalent to a risk of neuroblastoma of 64 106
(95% CI 30- 116) at 6 months. Furthermore. despite this
high detection rate at 3 weeks, the screening programme
detected two more cases at 6 months among 98 362 infants
tested and two cases diagnosed before 1 year were false
negatives, that is an additional 41 cases per million (95% CI
11-104). In other words, the risk of neuroblastoma in this
cohort is estimated at 105 per million in the first year of life.
From this same publication it can also be shown that the risk
of neuroblastoma before 22 months in the Quebec cohort is
at least (9 + 14) 171 151 = 134 106 (95% CI 85-202). These
figures are hardly compatible with the overall risk of neuro-
blastoma in Canada before screening (126 106). The first
results of feasibility trials in Lyon (Mathieu et al.. 1993) and
in Newcastle (Parker et al.. 1992) also support the above
conclusions about heavy overdiagnosis.
Expected prevalence at screening
The prevalence of subjects in the detectable preclinical phase
at screening. which is also the maximum proportion of the
target population who may benefit from screening, is a fun-
damental parameter of a screening programme. It depends
on the incidence of the disease. but more crucially on the
length of the detectable preclinical phase, also called sojourn
time. A long sojourn time implies higher detectability and
possibly greater benefit (Figure 2). This suggests that screen-
ing for a rare disease in children is a priori of low potential
benefit. However. an argument in favour of screening is a
large expected benefit in survival when the disease is detected
in its preclinical phase. This latter argument applies to
neuroblastoma if it is a progressive disease. In the present
section and the next. we address the quantitative aspect of
this question as if neuroblastoma was a single disease entity;
we first estimate the prevalence of detectable diseases and we
then use it to estimate the potential benefit of screening in
reducing mortality.
Assuming that the sensitivity of the HPLC test is 100%, a
case will be detected at screening if the sojourn time is
yp YO Yr, x z zp Time
-Lead time ------ Survival --t---Benefit--- (age)
Screening Incidence Death Death
(in the abscence of (in screen +)
screening)
Figure 2 Diagram show-ing the main concepts used in the
analvsis of screening efficacy yp and Y, denote the start of the
detectable preclinical phase in a screen positive and a screen
negative patient respectively.
greater than tix) = x -, w-here x is the age at incidence in
the absence of screening. and i0 the age at screening (Figure
2). Therefore. if Y denotes the age at the start of the detec-
table preclinical phase. the proportion of cases in a given
birth cohort that will be prevalent at screening is estimated
by:
prob( Y<Ko)
= jAx)p(I> (x))d-
!,,
(I)
that is the sum. over all ages greater than v0. of the cases
which would occur clinically at age x. in the absence of
screening (fx-)). and who would have a sojourn time
sufficiently long p( V> i(x)). This latter term has to be
estimated from a theoretical distribution reflecting present
knowledge on the duration of the preclinical phase of the
disease. For neuroblastoma. this knowledge is limited to
some indications that the average sojourn time is of the order
of 15 months (Berthold et al.. 1991). This information would
be sufficient to model the sojourn time distribution with an
exponential density which depends only on the mean sojourn
time. Since. however. the sojourn time is constrained to be
shorter than age (+ 9 months). it should have a lower mean
and variance for early-age tumours. Considering these
arguments. it was found more convenient to model sojourn
time with a Weibull distribution:
p( V> v) = exp (pILvY] (2)
where and p were chosen in such a way that the mean
sojourn time varied from 16 months for tumours occurring at
age 2 years up to 19 months for tumours occurring at 5
years. while the standard deviation varied from 7.4 to 22
months in the same age interval6.
The function f(x) was taken as the age distribution of
neuroblastoma in Europe. which was deduced from the inci-
dence given in Table I and from the age distribution of
patients in the first 2 years of life taken from French and
German data available to the Working Group. The preval-
ence of detectable disease is then estimated as the integral in
equation (1) multiplied by the cumulative risk of neuroblas-
toma; the prevalence is then well approximated by:
prev(vo) = F. Aj(x,+I
-x)p( V> (ii-yo)) (3)
where -x =(x- + xi, ,) 2 and A, is the incidence rate within the
interval x-1x, + . The quantity ,xi+I- x,) is shown as func-
tion of lx, in Figure 3.
Using this method, it was shown that screening at 12
months would anticipate substantially (more than 3 months)
the diagnosis for 20.5 cases per million children tested, lead-
ing to an expected prevalence of 34.5 106 after addition of the
incident cases at 12 months (± 3 months); screening at 18
months would lead respectively to 19 and 29 per million.
'Parameter p was taken to change linearlv with age and the distribu-
tion was truncated to meet the constraint v < + 9.0 24 48 72 96 120 144 148
Age (months)
Figure 3 Distribution of age at incidence used in the calculation
of prevalence at screening. Calculated from incidence in Europe
and from distribution of age at incidence observed in several
clinical series.
while screening at 12 and 18 months would anticipate the
diagnosis for a further 11.3 cases per million at the second
screen, and would detect overall 43 cases per million, of
which 32 would have an anticipated diagnosis. It is worth
noting that screening once at 6 months would anticipate the
diagnosis for only 24 cases per million, leading to an
expected prevalence of 40 106, a figure very different from
those observed in Japan and Quebec. suggesting that in these
two studies most cases prevalent at screening would never
have become incident.
Power of a mortality-based evaluation ofscreening
For logistic reasons the evaluation of screening efficacy pro-
posed up to now for neuroblastoma has been based on the
comparison of mortality in a screened population with that
in an unscreened population with similar neuroblastoma inci-
dence and mortality before screening. The basic design is as
follows:
Screening is offered to all children in a given population
according to the agreed screening procedure.
The number of deaths from neuroblastoma is recorded by
age and sex each year in the screened population and in
the control population.
. At year n after the start of screening. the cumulative
number of deaths in each screened birth cohort for which
a reduction in mortality is anticipated is compared with
the cumulative deaths in the same birth cohort of the
control population.
. The observed cohort-specific differences are accumulated
in a way similar to that used in other similar statistical
procedures (Cochran. 1954) with the proviso that the
analysis of homogeneity of the differences in younger and
older cohorts is carried out carefully as well as that of the
contribution of each cohort to the cumulative test statis-
tic.
The corresponding power of such a design depends on the
numbers of births in the screened and control populations.
the anticipated reduction in mortality, the number of birth
cohorts enrolled and the number of years of follow-up (see
Figure 4). The expected number of deaths contributed by
subjects detected at screening was calculated from the
expected prevalence and from the survival probability of
cases detected by screening. The values of these latter pro-
babilities were based on clinical experience and were made
dependent on the anticipation of diagnosis by screening
(Table III). The number of expected deaths contnrbuted by
those unscreened or undetected at screening was calculated
from a survival curve with the shape shown in Figure 1, and
adjusted to give the age-specific 5 year survival provided by
the ENSG database (see Table II). Expected mortality in the
screened and unscreened populations was thus obtained from
the incidence, prevalence and survival, and the resulting
figures are given in Table IV. It is seen that the reduction is
around 15% for one screen whatever the age at screening.
9
10 Recruitment Follow-up
Di, deaths in the ith screened birth cohort
Ei, deaths in the ith control birth cohort
Figure 4 Design of a possible trial for testing neuroblastoma
screening efficacy. The test consists of a comparison between Di
and Ei, the evidence is accumulated over the six cohorts followed
up.
Table III Survisal probability (00) of screen-detected cases
according to anticipation of diagnosisa
Anticipation Months since diagnosis
(Years, 12 36 60 120
<1 97 87 85 85
1 -2 99 88 86 85
>2 99 97 90 89
aThe anticipation of diagnosis is defined as the difference between
age at screening and age at which the tumour would have been
clinically diagnosed.
Table IV Expected cumulative mortality from neuroblastoma in
screened and unscreened European populations
Age (jears a
0 2 5 7 10 14
No screening 2.9 18.4 44.4 54.5 60.9 64.4
Screening age (months)
6 3.1 1 1.9 35.0 44.8 51.1 54.6
12 2.9 14.5 34.6 44.0 50.3 53.7
18 2.9 18.1 35.1 44.0 50.2 53.4
12 + 18 2.9 14.5 29.2 37.7 43.8 47.0
aCumulative nrsk up to the end of this year of age.
and a little more than 25% for two screens at 12 and 18
months. Using these figures. the statistical power has been
calculated as a function of the number of births each year in
the screened cohort and in the control cohort, the number of
years of enrolment and the length of follow-up. The results
are shown in Table V. Note that these results are of an order
of magnitude compatible with those provided by Prorok
(1992) but are at variance with those given by Woods et al.
(1992a). who based their power calculation on an unrealistic
reduction of mortality of 57%.
Discussio
There is a dogma among epidemiologists which states that
when a screening programme has been offered as a service to
a population without prior evaluation being made, it is no
longer possible to make such an evaluation in this popula-
tion. However, it is useful to remember that screening for
cervical cancer has been evaluated in this way (Hakama et
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6Table V Power of a tnral for neuroblastoma screening efficacy by
age at screening and number of children screened each year
Recruitment (Years)hv
Age at Number of 5 7 10
screening birth year Follow-up Follow-up Follow-up
(months) (million) 0 5 0 5 0 5
6 0.5 0.52 0.46 0.62 0.56 0.73 0.68
1.0 0.77 0.71 0.87 0.82 0.94 0.91
12 0.5 0.39 0.51 0.53 0.62 0.68 0.74
1.0 0.61 0.76 0.78 0.86 0.91 0.94
18 0.5 0.31 0.50 0.46 0.62 0.63 0.74
1 0.50 0.76 0.70 0.86 0.87 0.95
12 + 18 0.25 0.37 0.62 0.55 0.74 0.74 0.85
0.5 0.58 0.87 0.81 0.94 0.94 0.98
'Under the hypothesis of the same number of births in the control
population and supposing that compliance is 100%. bNumber of
birth cohorts entering the study population. Only a subset of them
are informative if the analysis is done at follow-up 0: the number of
informative cohorts depends on the age at screening (see Figure 4).
al.. 1986): it would therefore be surprising if the five million
children who have been screened for neuroblastoma in Japan
could not shed light on the efficacy of screening for neuro-
blastoma.
First, after an analysis of the results of this programme. it
was clearly demonstrated that screening at an early age
(before 6 months) is inadvisable because of overdiagnosis
(Murphy et al.. 1991). These results are essential in the
planning of future trials. It is hoped that the figures we have
produced in the present article will reinforce this consensus.
Our prevalence results may even be considered optimistic.
since we have not taken the sensitivity of the test into
account. This parameter is in fact poorly known. and sen-
sitivity may be implicitly modelled through the distribution
of sojourn time by putting more weight towards zero.
Furthermore, the mean sojourn time may have been overes-
timated. This estimate is based on 18 cases of localised
neuroblastoma, which later progressed towards metastatic
disease, and which would represent failure in the screening
context; it is difficult to assess the extent to which this
estimate can be extrapolated to neuroblastomas which would
benefit from being screened at an early stage. It is. however.
unlikely that the sojourn time is lower on average among
'good' cases, except if these are less often excretors of
catecholamine metabolites (Berthold et al.. 1991).
Secondly. study of the false negatives observed in the
Japanese screening programme should help us to understand
more precisely the natural history of the disease. but very few
such studies have been published. An analysis of 13 false
negatives suggests that the preclinical phase was shorter than
17 months on average (range 1 -54) (Nakagawara et al..
1991). Another six false negatives were detected between ages
23 and 47 months (Ishimoto et al., 1990). Taking the two
series together, 50% of the false negatives had a sojourn time
less than 17 months, suggesting that the mean sojourn time
used in our calculation is unlikely to be an underestimate.
The variance of the distribution of sojourn time is at best
roughly estimated. It is. however, likely that it is less precise
for late cases, who contribute very little to the prevalence at
screening ( 1 % from age 5 months onwards). Although the
parameters of the distribution of sojourn time may be poorly
estimated, changing their values within an acceptable range
defined by the empirical evidence described above would not
drastically change the results for the expected prevalence.
Consequently, it may be concluded from the Japanese data
on screening and from the most recent results in Quebec that
overdiagnosis when screening before 6 months is probably of
the order of 80 cases per million. Such a figure is disturbing.
and the reason for such a heavy overdiagnosis needs to be
explored further. In the meantime. evaluation of screening at
12 or 18 months. or both. could be considered. Such a study.
however. would need to enrol between 0.5 and 1 million
children per year in both the screened and unscreened
cohorts: it would also need international collaboration
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between several groups who have already demonstrated the
feasibility of such an undertaking from the logistic point of
view (compliance. laboratory tests. etc.). Screening twice
would have obviously several advantages, including the col-
lection of more relevant biologiical information on the disease
natural historx-.
Thirdly. despite overdiagnosis. it is possible that being
screened at 6 months confers some protection against neuro-
blastoma: this hypothesis could be tested through a case-
control study of neuroblastoma deaths or of stage IV
patients (Sasco et al.. 1986). This study might also shed some
light on the length of the detectable preclinical phase. if a
protective effect were demonstrated. The selection bias. which
is a classical difficulty of this approach (Moss. 1991: Weiss et
al.. 1992). should be less severe in the present instance. since
it is unlikely that the children who were not screened are a
priori at a higher risk of the disease.
In recent years. considerable advances have been made in
the cytogenetic and molecular analysis of tumour tissue. and
several authors have concluded that neuroblastoma is a
heterogeneous disease (Brodeur et al.. 1992: Hayashi et al..
1992: Woods et al.. 1992b). Loss of heterozygosity for the
short arm of chromosome 1. amplification of the N-mvc
oncogene. and near-diploid or tetraploid karyotype are three
unfavourable markers which are strongly linked with age at
incidence and stage and therefore with prognosis. It remains
to be clarified whether a neuroblastoma with favourable
markers can evolve into a disease with unfavourable ones. It
has in fact been known for a long time that children diag-
nosed with a disseminated disease before the age of 1 year
have a better prognosis than those diagnosed after that age
with an apparently similar disease (De Bernardi et al.. 1992).
It has even been necessarn to create a special classification
for some disseminated stages (no bone metastasis) occurring
before 1 year because of their tendency to regress spontan-
eously after surgery (stage IVs). In addition, several analyses
of the survival of stage IV patients have shown a clear effect
of age. suggesting that stage IV includes several steps or
consists of late stages of several diseases of different malig-
nancy. Answering these questions is crucial in order to judge
the potential efficacy of screening. The recent demonstration
that high expression of the TRK protooncogene. which is
implicated in the responsiveness of cells to the nerve growth
factor. is correlated with early stage and stage IVs of the
disease lends more support to the hypothesis of disease
heterogeneity. High TRK expression in tumours occurring in
infants (<12 months) without N-mYc amplification may per-
mit discnrmination between tumours which will differentiate
or regress and those which need more aggressive treatment
(Nakagawara et al.. 1993). Along similar lines. high expres-
sion of CD44 cell-surface glycoprotein has shown to be a
marker of good prognosis: it was found in all of the 2"
favourable stages examined. and in 15 out of 30 advanced
stages for which it was predictive of a more favourable
outcome (Combaret et al.. 1994). The various markers are
highly correlated. and it is difficult at present to determine
their specific role in the progression of the disease. let alone
the biological mechanism involved. Multivariate analyses of
small series of cases may be misleading. since the association
observed in these series may not be representative of the real
correlation in the case population. It is therefore not surpris-
ing that the prognostic value of markers is difficult to sum-
marise. The following statement can probably be made with
some confidence: ploidy is highly predictive among infants.
but not among children older than 24 months (Look et al..
1991) and N-mvc amplification is associated with ploidy but
has independent predictive value (Bourhis et al.. 1991: Look
et al.. 1991). Deletion of 1 p may precede the development of
N-mvc amplification. which may be the important factor
(Brodeur et al.. 1992). Considering all the evidence together.
and given that ploidy and probably N-mv-c amplification
(Brodeur et al.. 1987) are characteristics of the tumour at its
early stage. we can guess that between 10% and 30% of the
tumours will not respond to current treatment. whatever the
age at which they are diagnosed. and another unknown
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proportion would do well without treatment: the remaining
tumours are those that could benefit from screening. A
reliable estimate of their proportion is almost impossible
from the available information. but the above discussion
implies that the anticipated 25% reduction in mortality is
probably greater than what can be achieved by screening.
The definitive answer may be provided by conducting a trial.
if it can be shown that overdiagnosis is kept at a reasonable
level when screening is performed at 12 months or after. The
latter condition would be fulfilled if the incidence of the less
aggressive disease. which is clearly overdiagnosed by early
screening. diminishes rapidly to zero after birth. as suggested
by several observations (see the definition of stage IVs neuro-
blastoma). Such a trial would have the further advantage of
providing a population-based biological study of this disease.
which would help to answer several of these challenging
questions.
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